Omeros Corporation (NASDAQ:OMER) dropped 3.5% on Wednesday . The stock traded as low as $11.43 and last traded at $11.68, with a volume of 266,217 shares traded. The stock had previously closed at $12.10.

OMER has been the topic of several analyst reports. WBB Securities reiterated a “buy” rating and issued a $75.00 target price on shares of Omeros Corporation in a report on Tuesday, June 14th. Maxim Group reiterated a “buy” rating and issued a $30.00 target price on shares of Omeros Corporation in a report on Thursday, May 19th. FBR & Co reiterated an “outperform” rating and issued a $38.00 target price on shares of Omeros Corporation in a report on Wednesday, June 29th. Cantor Fitzgerald initiated coverage on shares of Omeros Corporation in a report on Thursday, June 2nd. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $62.00 target price on shares of Omeros Corporation in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Omeros Corporation currently has an average rating of “Buy” and a consensus target price of $38.22.

The company has a 50 day moving average price of $11.12 and a 200 day moving average price of $12.29. The company’s market cap is $437.92 million.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.11. The business had revenue of $7.40 million for the quarter, compared to analysts’ expectations of $8.79 million. During the same quarter last year, the firm earned ($0.51) earnings per share. Omeros Corporation’s revenue was up 1797.4% on a year-over-year basis. Equities research analysts predict that Omeros Corporation will post ($1.76) EPS for the current year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $11.42, for a total transaction of $181,578.00. Following the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,049,855.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Other large investors have bought and sold shares of the company. Nationwide Fund Advisors raised its stake in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares during the last quarter. California State Teachers Retirement System raised its stake in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 1,249 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock worth $1,827,000 after buying an additional 694 shares during the last quarter. Brown Advisory Inc. raised its stake in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock worth $8,332,000 after buying an additional 163,306 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock worth $20,885,000 after buying an additional 454,055 shares during the last quarter.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.